<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044381</url>
  </required_header>
  <id_info>
    <org_study_id>TP-0901-S</org_study_id>
    <nct_id>NCT01044381</nct_id>
  </id_info>
  <brief_title>Open-Label Pharmacokinetics (PK)/Safety Study of Luliconazole Solution, 10% in Distal Subungual Onychomycosis</brief_title>
  <official_title>A Phase 1/2a, Open-Label Study Evaluating the Pharmacokinetics, Safety and Tolerability of Luliconazole Solution, 10% in Subjects With Moderate to Severe Distal Subungual Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topica Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topica Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, tolerability, systemic exposure and pharmacokinetics of luliconazole
      after repeat daily topical application of Luliconazole Solution, 10% in a maximal use setting
      in adults with distal subungual onychomycosis of the toenails.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters (AUC, Cmax, Tmax, t1/2) will be measured at days 1 (Baseline), 9, 15 and 29. Safety assessments include monitoring of adverse events, local site tolerability, ECG monitoring, and changes in laboratory values and vital signs.</measure>
    <time_frame>March 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of linear toenail growth.</measure>
    <time_frame>March 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Luliconazole Solution, 10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luliconazole Solution, 10%</intervention_name>
    <description>28 days of daily application</description>
    <arm_group_label>Luliconazole Solution, 10%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years

          -  Distal Subungual Onychomycosis(DSO)on both great toenails with &gt;=50%involvement of at
             least 1 great toenail

          -  At least 4 additional toenails with DSO

          -  Positive KOH and culture

          -  Normal renal and hepatic function

        Exclusion Criteria:

          -  Subjects with hypersensitivity to imidazole compounds or any other ingredient

          -  Subjects unwilling to refrain from use of nail cosmetics until end of study

          -  Subjects with symptomatic tinea pedis

          -  Subjects with any history of cardiac disease of cardiac rhythm abnormalities

          -  Female subjects who are pregnant, nursing, or planning a pregnancy

          -  Subjects who have not undergone the specified washout period(s) for the following or
             requiring the concurrent use of: topical antifungal within 4 weeks; topical
             anti-inflammatory, corticosteroids, topical immunomodulators within 2 weeks; systemic
             corticosteroids within 2 weeks; systemic immunomodulators within 4 weeks.

          -  Subjects receiving systemic antifungals for treatment of onychomycosis or any systemic
             antifungal with known activity against dermatophytes within the previous 12 weeks or 5
             half-lives of the drug, whichever is longer

          -  Subjects receiving any other treatment/therapy for the onychomycosis not previously
             mentioned (e.g., laser treatment) within 4 weeks

          -  Subjects with a history of significant internal disease or with a life threatening
             condition within the last 6 months

          -  Subjects with anatomic abnormalities of the toe(s) and or toenails

          -  Subject who have donated or lost a large volume of blood (~500 mL or more, during the
             previous 6 weeks

          -  Subjects with a recent history of or currently known to abuse drugs or alcohol

          -  Subjects currently participating in another investigational medication or device study
             or have participated in a clinical trial within 30 days or five half-lives of the test
             medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry M Jones, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>J&amp;S Studies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>J&amp;S Studies</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <disposition_first_submitted>June 13, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 19, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 22, 2011</disposition_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Toenail</keyword>
  <keyword>Fungal Infections</keyword>
  <keyword>DSO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

